Kimberly Rao
Family · Alexandria, LANPI 1811203318
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $72,698 of the $83,739 with a category attached, or 86.8%. AbbVie accounts for 90.1% of it on its own, with 15 other manufacturers making up the rest. Among family clinicians in LA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 755 payments — averaging $110.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$75K
- Biohaven Pharmaceutical Holding Company Ltd.$3K
- Pfizer$1K
- Teva Pharmaceuticals USA, Inc.$1K
- Biohaven Pharmaceuticals, Inc.$683
- Lundbeck LLC$571
- plus $1K from 10 others
Across 2 payments — averaging $5375.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Biohaven Pharmaceutical Holding Company Ltd.$6K
- Pfizer$5K
What the payments were for
- Consulting fees$6751%
- Speaking & faculty fees$72,69887%
- Food & beverage$10,15112%
- Education$2150%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 442 | $75,418 |
| Biohaven Pharmaceutical Holding Company Ltd. | 35 | $3,370 |
| Pfizer | 45 | $1,249 |
| Teva Pharmaceuticals USA, Inc. | 60 | $1,080 |
| Biohaven Pharmaceuticals, Inc. | 54 | $683 |
| Lundbeck LLC | 37 | $571 |
| Amgen | 25 | $375 |
| Lilly USA, LLC | 17 | $278 |
| Impel Pharmaceuticals Inc. | 7 | $191 |
| Axsome Therapeutics, Inc. | 9 | $176 |
| Currax Pharmaceuticals LLC | 12 | $133 |
| Supernus Pharmaceuticals, Inc. | 5 | $78 |
| Novartis | 3 | $53 |
| Saol Therapeutics Inc. | 1 | $43 |
| Amneal Pharmaceuticals LLC | 2 | $29 |
| Upsher-smith Laboratories LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$83,739 in reported general payments places this provider in the 95th percentile of 3,610 family providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Nurtec OdtRimegepant Sulfate | 74 | $135,078 |
| UbrelvyUbrogepant | 61 | $80,611 |
| BotoxOnabotulinumtoxina | 43 | $53,125 |
| Aimovig AutoinjectorErenumab-Aooe | 67 | $52,125 |
| QuliptaAtogepant | 35 | $50,403 |
| Emgality PenGalcanezumab-Gnlm | 58 | $50,155 |
| Ajovy AutoinjectorFremanezumab-Vfrm | 18 | $18,118 |
| Ondansetron OdtOndansetron | 74 | $1,400 |
| RizatriptanRizatriptan Benzoate | 82 | $1,174 |
| Amitriptyline Hcl | 139 | $1,152 |
| Tizanidine Hcl | 109 | $839 |
| Naproxen | 94 | $657 |
| Sumatriptan Succinate | 59 | $609 |
| Topiramate | 86 | $526 |
| Prochlorperazine Maleate | 48 | $468 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieUbrelvy, Botox, Qulipta | $75,418 | $184,139139 claims |
| PfizerNurtec Odt | $1,249 | $135,07874 claims |
| Upsher-smith Laboratories LLCTopiramate | $13 | $52686 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,610 family providers in Louisiana.
Other family in Alexandria
- Lacey LemoineAlexandria$25K
- Kimberly LabordeAlexandria$14K
- Rebecca EzellSlidell$268K
- Erin PierceNew Orleans$261K
- Tavell KindallNew Orleans$194K
- Ashlea HillRuston$169K
- Brittany MillerVille Platte$158K
- Ryanne ClarkeGretna$123K
- Elidia DewittBaton Rouge$108K
- Rebekah GarrardLafayette$105K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.